Alto Neuroscience (ANRO) Total Debt (2023 - 2026)

Alto Neuroscience has reported Total Debt for 4 years, with the latest figure at $16.0 million in Q1 2026.

• Quarterly Total Debt fell 19.65% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (down 19.65% YoY) and the FY2025 annual result came in at $16.8 million, up 63.42% from the prior year.
• Total Debt declined to $16.0 million in Q1 2026 per ANRO's latest filing, from $16.8 million in the prior quarter.
• Over five years, Total Debt peaked at $20.3 million in Q3 2025 and troughed at $9.9 million in Q4 2023.
• A 4-year average of $15.0 million and a median of $14.9 million in 2024 frame the typical range for Total Debt.
• The sharpest annual moves came in 2025 and 2026: Total Debt surged 79.54% in 2025, then fell 19.65% in 2026.
• Over 4 years, Total Debt stood at $9.9 million in 2023, then increased by 3.99% to $10.3 million in 2024, then soared by 63.42% to $16.8 million in 2025, then decreased by 4.39% to $16.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $16.0 million, $16.8 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.